cmpd-1

CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).

PRMT4-IN-1 is a selective inhibitor of PRMT4, demonstrating an IC50 value of 3.2 nM, and has been shown to reduce the relative viability of MCF7 cells [1].

CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM). Which can be used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively.

Takeda103A (CMPD103A) is the GRK2-dependent bovine tubulin oxidation effective inhibitor.

CMPD167 (MRK-1) is a potent, orally active inhibitor of CCR5 with significant in vitro antiviral efficacy [1].

CMPD101 hydrochloride is a membrane-permeable small molecule inhibitor of GRK2 and GRK3, exhibiting IC50 values of 18 nM and 5.4 nM, respectively. This compound also inhibits Rho-associated kinase 2 (ROCK-2) and PKCα, with IC50 values of 1.4 μM and 8.1 μM, respectively.

β2AR antagonist 1 (Cmpd-15PA) acts as an antagonist to the β2 adrenergic receptor (β2AR). This compound binds to the intracellular surface of β2AR.

(R)-CMPD-39 is the R-enantiomer of CMPD-39. CMPD-39 acts as a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 with an IC50 of approximately 20 nM and demonstrates high selectivity for other DUB family members at concentrations ranging from 1-100 μM. By inhibiting USP30's deubiquitination activity, CMPD-39 enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP and promotes the accumulation of phosphorylated ubiquitin. This process accelerates both mitophagy and pexophagy. Additionally, CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson’s disease patients.